This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Albert Pinhasov (Hebrew: אלברט פנחסוב; born 9 February 1972) is the Rector of Ariel University. He is a researcher in the fields of Molecular Psychiatry and Psychopharmacology.He also served as Vice President and Dean for Research & Development and the Head of the Department of Molecular Biology at Ariel University. Albert Pinhasov was born on 9 February 1972 in the city of Namangan, Uzbekistan. From 1990 to 1994, he studied at the Gorky Academy of Medicine, in the city of Nizhny Novgorod, Russia. In 1994, he immigrated to Israel where he continued his education at Tel Aviv University. He was awarded a Master of Science degree (MSc) in 1998 and a PhD in the field of Molecular Biology and Clinical Biochemistry under the mentorship of Illana Gozes in 2002 from Tel Aviv University.
Negative mass selection, which is removal of plants/seeds with unwanted properties, can be done when preparing seed for planting, at field visits during the growing season and at harvest. Removing unhealthy/deceased plants from the field is a simple way to improve the population. Before planting it is normal procedure to clean the seed to remove seeds from weeds and this will also remove small seeds, introducing a weak selection towards bigger kernels. Seed can also be sorted according to color or protein content.
Nucleic acid (DNA and RNA) strands with corresponding sequences stick together in pairwise chains. But each node of the chain is not very sticky, so the double-stranded chain is continuously coming partway unzipped and re-zipping itself under the influence of ambient vibrations (referred to as thermal noise or Brownian motion). Longer pairings are more stable. Nucleic acid tests use a "probe" which is a long strand with a short strand stuck to it. The long primer strand has a corresponding (complementary) sequence to a "target" strand from the disease organism being detected. The disease strand sticks tightly to the exposed part of the long primer strand (called the "toehold"), and then little by little, displaces the short "protector" strand from the probe. In the end, the short protector strand is not bound to anything, and the unbound short primer is detectable. The rest of this section gives some history of the research needed to fine-tune this process into a useful test.
Dmitri Leonidovich Romanowsky (sometimes spelled Dmitry and Romanowski, Russian: Дмитрий Леонидович Романовский; 1861–1921) was a Russian physician who is best known for his invention of an eponymous histological stain called Romanowsky stain. It paved the way for the discovery and diagnosis of microscopic pathogens, such as malarial parasites, and later developments of new histological stains that became fundamental to microbiology and physiology. While working on his doctoral research, Romanowsky developed the first effective staining method for malarial parasite in 1890. Using a specific mixture of mouldy methylene blue and eosin, he found that malarial parasites could be distinctively identified from other blood cell and within the red blood cells. The chemical reaction of such staining is known in chemistry as "Romanowsky effect". The method became the gold standard in malaria detection by microscopy and general immunohistochemistry. British zoologist and science historian, Francis Edmund Gabriel Cox remarked the discovery as a serendipitous case that became "one of the most significant technical advances in the history of parasitology."
Sources: en.wikipedia.org
Hazard research is published: the annual Global Carbon Budget study finds fossil CO2 emissions are still rising when if they stayed the same, the 50% likelihood to limit global warming to 1.5 °C would be exceeded around 2031 (5 Dec), the genetic testing company 23andMe confirms that the genetic privacy of around 7 million customers has been violated in the 23andMe data leak (5 Dec), a study using plasma proteomics aging clocks suggests nearly 20% of the population may show strongly accelerated age in one of 11 major organs, which it links to higher mortality risk (6 Dec), cumulative loneliness in mid-to-later life, a growing public health concern, is confirmed as potential substantial excess mortality risk factor with U.S. data (11 Dec), news outlets report on a study (13 Oct) finding ~82% of fish samples from two Michigan watersheds exceed daily consumption limit for adults of total PFOS (12 Dec), a study robustifies the link between women's preconception exposure to phthalates and lower fecundability, changes in reproductive hormones, and increased inflammation using EAGeR trial data (13 Dec), a study of meal timing using French NutriNet-Santé data indicates longer nighttime fasting periods may be superior to breakfast skipping in intermittent fasting (14 Dec), one of the first horizon scan risk screening studies by region on invasive species threats identifies 40 high-risk potential invaders to Florida (14 Dec).
There are two types of construction: the series of adjacent buildings in an enclosure around a common, and the round huts with grass roof. The round huts with grass roof architecture are situated in the northern regions, while the series of adjacent buildings are in the southern regions. Postmodern architecture and high-tech architecture buildings are in the southern regions, while heritage sites are evident in the more than 30 forts and castles in the country, such as Fort William and Fort Amsterdam. Ghana has museums that are situated inside castles, and two are situated inside a fort. The Military Museum and the National Museum organise temporary exhibitions. Ghana has museums that allow an in-depth look at specific regions, with a number of museums providing insight into the traditions and history of the geographical areas. The Cape Coast Castle Museum and St. George's Castle (Elmina Castle) Museum offer guided tours. The Museum of Science and Technology provides its visitors with a look into the domain of scientific development.
Lymphocyte Lymphocytes, which are the second most common type of white blood cell in adults, are typically small cells with a round, dark nucleus and a thin strip of pale blue cytoplasm. Some lymphocytes are larger and contain a few blue granules. Increased lymphocyte counts (lymphocytosis) can be caused by viral infections and may also occur after splenectomy. Children have higher lymphocyte counts than adults. Chronic lymphocytic leukaemia presents with an elevated lymphocyte count and abnormal lymphocyte morphology, in which the lymphocytes have extremely dense, clumped nuclei and some cells appear smudged on the blood smear. Low lymphocyte counts (lymphopenia) may be seen in infections such as HIV/AIDS, influenza and viral hepatitis, as well as in protein-energy malnutrition, acute illnesses and drug reactions. In response to viral infections (especially infectious mononucleosis), lymphocytes may increase greatly in size, developing unusually shaped nuclei and large amounts of dark blue cytoplasm. Such cells are referred to as reactive or atypical lymphocytes and when present they are either commented on or counted separately from normal lymphocytes in the manual differential.
=== Mechanism of action === Eluxadoline is a μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist that acts locally in the enteric nervous system, possibly decreasing adverse effects on the central nervous system.
includes measurements of radioactivity in plasma, including metabolite correction. From the two-tissue compartment model and by assuming there is only passive diffusion across the blood brain barrier, one obtains:
Sources: en.wikipedia.org
Non-focal symptoms such as amnesia, confusion, incoordination of limbs, unusual cortical visual symptoms (such as isolated bilateral blindness or bilateral positive visual phenomena), headaches and transient loss of consciousness are usually not associated with TIA, however patient assessment is still needed. Public awareness on the need to seek a medical assessment for these non-focal symptoms is also low, and can result in a delay by patients to seek treatment Symptoms of TIAs can last on the order of minutes to one–two hours, but occasionally may last for a longer period of time. TIA is defined as ischemic events in the brain that last less than 24 hours. Given the variation in duration of symptoms, this definition holds less significance. A pooled study of 808 patients with TIAs from 10 hospitals showed that 60% lasted less than one hour, 71% lasted less than two hours, and 14% lasted greater than six hours. Importantly, patients with symptoms that last more than one hour are more likely to have permanent neurologic damage, making prompt diagnosis and treatment important to maximize recovery.
== Function == Although the function of alpha-synuclein is not well understood, studies suggest that it plays a role in restricting the mobility of synaptic vesicles, consequently attenuating synaptic vesicle recycling and neurotransmitter release. An alternate view is that alpha-synuclein binds to VAMP2 (a synaptobrevin) and stabilizes SNARE complexes; though recent studies indicate that alpha-synuclein–VAMP2 binding is critical for alpha-synuclein-mediated attenuation of synaptic vesicle recycling, connecting the two seemingly divergent views. It may also help regulate the release of dopamine, a type of neurotransmitter that is critical for controlling the start and stop of voluntary and involuntary movements. Alpha-synuclein modulates DNA repair processes, including repair of double-strand breaks (DSBs). DNA damage response markers co-localize with alpha-synuclein to form discrete foci in human cells and mouse brain. Depletion of alpha-synuclein in human cells causes increased introduction of DNA DSBs after exposure to bleomycin and reduced ability to repair these DSBs. In addition, alpha-synuclein knockout mice display a higher level of DSBs, and this problem can be alleviated by transgenic reintroduction of human alpha-synuclein. Alpha-synuclein promotes the DSB repair pathway referred to as non-homologous end joining. The DNA repair function of alpha-synuclein appears to be compromised in Lewy body inclusion bearing neurons, and this may trigger cell death.
1 January – New Year's Day 16–17 February – Carnival 3 April – Good Friday 21 April – Tiradentes's Day 1 May – Labour Day 4 June – Feast of Corpus Christi 7 September – Independence Day 12 October – Our Lady of Aparecida 2 November – All Souls' Day 15 November – Republic Day 20 November – Black Consciousness Day 25 December – Christmas Day 31 December — New Year's Eve
=== Aging === Tissue homeostasis generally declines with age, in part because stem/progenitor cells fail to self-renew or differentiate. Skin aging is caused in part by TGF-β by blocking the conversion of dermal fibroblasts into fat cells which provide support. Common changes in the skin as a result of aging range from wrinkles, discoloration, and skin laxity, but can manifest in more severe forms such as skin malignancies. Moreover, these factors may be worsened by sun exposure in a process known as photoaging.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.